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Abstract
Mycobacterium smegmatis (Ms) is a nonpathogenic mycobacteria of rapid growth, which shares many
characteristics with Mycobacterium tuberculosis (MTB), the major causative agent of tuberculosis. MTB has several
cell wall glycolipids in common with Ms, which play an important role in the pathogenesis of tuberculosis and the
induction of a protective immune response against MTB infection in some animal models. In this study, the
humoral immune response and cross reactivity against MTB, of liposomes containing a mixture of cell wall
glycolipids of Ms and commercial lipids was evaluated, in order to study its possible use as a component of a
vaccine candidate against tuberculosis. Liposomes containing total lipids extracted from Ms, distearoyl phosphatidyl
choline and cholesterol were prepared by the dehydration-rehydration technique. Balb/c mice were immunized
with the liposomes obtained and the antibody response and cross reactivity against MTB were tested by ELISA.
Total lipids extract from Ms showed the presence of several polar glycolipids in common with MTB, such as
phosphatidylinositol mannosides. Liposomes that contained glycolipids of Ms were capable of inducing a specific
IgG antibody response that allowed the recognition of surface antigens of MTB. The results of this study
demonstrated the presence of immunogenic glycolipids in Ms, which could be included to enhance the protective
effects of subunit vaccine formulations against tuberculosis.
Introduction
Tuberculosis (TB) is still one of the most lethal infectious
diseases worldwide [1]. The only TB vaccine available for
human use is the bacille Calmette-Guerin (BCG), an atte-
nuated strain of Mycobacterium bovis [2]. However, this
vaccine protects only against the most severe forms of the
disease during childhood and their effectiveness has failed
in the adult population. In recent years various glycolipids
of the mycobacterial cell wall have become attractive
candidates for a vaccine against TB because they consti-
tute important virulence factors for initiating the establish-
ment of infection by MTB [3]. These glycolipids have been
demonstrated to be capable of stimulating T lymphocytes
through the presentation by CD1 molecules [4]. In addi-
tion, mycobacterium lipids have been shown to induce
protection in certain experimental animal models against
infection by MTB [5,6]. Some of these glycolipids are pre-
sent in the cell wall of Mycobacterium smegmatis (Ms), a
non-pathogenic mycobacteria of rapid growth, which has
been used as a study model for TB. Liposomes prepared
from glycolipids of Ms have also been reported to possess
immunoadjuvant capacity [7]. Hence, it is interesting to
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evaluate the use of cell wall glycolipids of Ms as potential
vaccine candidates against TB. Therefore, this study aims
to assess the humoral immune response and cross reactiv-
ity induced by immunization of mice with liposomes con-
taining a mixture of Ms total lipids and commercial lipids
against MTB cell wall antigens.
Materials and methods
Total lipids from Ms mc2 155 were extracted according to
the methodology proposed by Rosenkrands et al [8].
Briefly, 30 mL of chloroform: methanol (2:1) was added to
10 g wet weight of biomass and mixed in a shaker over-
night at room temperature. The chloroform phase and the
extracted lipids were analyzed by one dimensional TLC.
Liposomes were prepared according to the technical pro-
cedure of dehydration-rehydration [9]. Lipid composition
of liposomes was basically distearoyl phosphatidyl choline
(Sigma) and cholesterol (Sigma) at a molar ratio 1:1. Ten
mg of Ms total lipids was then added to this mixture.
Balb/c mice between 8 to 12 weeks were used in this
study. Mice were divided into 4 groups of 10 animals each
and were immunized subcutaneously with the appropriate
preparation obtained as described below. Two control
groups were used: the negative control group received 0.1
mL of PBS and the positive control group recieved 5 x 106
CFU of M. bovis BCG Danish strain. Another group
received 0.1 mL of a liposomal preparation formulated
with commercial lipids (LipE) and a third group was
inoculated with 0.1 mL of a liposomal preparation con-
taining 1 mg of Ms total lipids and commercial lipids
(LipMs). Groups inoculated with the liposome preparation
(LipE and LipMs) received 3 doses administered 21 days
apart from each other. The humoral immune response
and cross reactivity against MTB was evaluated by indirect
ELISA using Ms total lipid and subcellular fraction of
MTB cell wall (CW), respectively.
Results and discussion
Recognition of Ms total lipids by IgG antibodies in the
sera of animals immunized with LipMs (Figure 1), was sig-
nificantly higher than that of other groups. However, no
significant differences were observed in the sera of animals
inoculated with LipE and PBS against lipids from Ms. This
result shows that the response obtained with LipMs, is
due to the presence of the lipids from Ms and not to the
commercial lipids used for preparation of liposomes. IgG
Figure 1 Specific recognition of total lipids of Ms by IgG antibodies present in the sera of mice immunized with liposomes containing lipids of Ms.
NC: negative control (PBS), BCG: M. bovis BCG, LipE: liposomes prepared only with commercial lipids, LipMs: liposomes prepared with total lipids of
Ms. (*) Significant difference compared to other groups, p <0.05.
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antibodies against CW of MTB and BCG was detected in
the sera of animals immunized with LipMs (Figure 2). The
cross reactivity is possibly due to the presence of some gly-
colipids in the LipMs that share epitopes in common with
MTB and BCG. Moreover, TLC analysis showed the pre-
sence of several common polar glycolipids in Ms and
MTB like phosphatidylinositol mannosides (PIMs). This
lipids have been demonstrated to play an important role
in the infection of macrophages and to have the potential
to induce humoral immune response capable of conferring
protection against infection with MTB in experimental
mouse models [10].
In this study, we demonstrated that total lipids of Ms
included in liposomes are able to induce humoral immune
response in mice and posses cross-reactivity to MTB.
These results support the strategy of employing Ms as a
possible source of lipid antigens to be part of a vaccine
candidate against TB.
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